Artificial-intelligence (AI)-driven drug discovery company, Exscientia, has revealed that Sanofi will be advancing an innovative bispecific small-molecule project that was discovered through the companies modality collaboration, formed in 2017.
In an Aug. 5, 2019 press release, ExscientiaOriginal Article
